secwatch / observer
8-K filed September 1, 2023, 7:59 PM ET ticker FEED CIK 0001326706
other material confidence high sentiment neutral materiality 0.60

NanoVibronix raises ~$5M in private placement of common stock and warrants

ENvue Medical, Inc.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

ENvue Medical, Inc. entered into Securities Purchase Agreement with institutional investor valued at 180,000 shares common stock, pre-funded warrants for 2,726,977 shares, A-1 Warrants for 2,906,977 sh (effective 2023-08-30).

Action
entry
Agreement
equity purchase
Counterparty
institutional investor
Value
180,000 shares common stock, pre-funded warrants for 2,726,977 shares, A-1 Warrants for 2,906,977 sh
Effective
2023-08-30
Exact text from the filing
On August 30, 2023, NanoVibronix, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with an institutional investor for the issuance and sale in a private placement (the “ Private Placement ”) of 180,000 shares (the “ Common Shares ”) of common stock, par value $0.001 per share (the “ Common Stock ”) , pre-funded warrants (“ Pre-Funded Warrants ”) to purchase up to 2,726,977 shares of common stock, with an exercise price of $0.0001 per share, A-1 Warrants (the “ A-1 Warrants ”) to purchase up to 2,906,977 shares of Common Stock, with an exercise price of $1.47 per share, and A-2 Warrants (the “ A-2 Warrants ” and together with the A-1 Warrants, the “ Warrants” ) to purchase up to 2,906,977 shares of Common Stock with an exercise price of $1.47 per share.
View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

ENvue Medical, Inc. filing history →

Source: SEC EDGAR
accession 0001493152-23-031487
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.